Cost of treatment for children with acute lymphoblastic leukemia in Bangladesh
Introduction
In high-income countries at least 75–80% of children with cancer, particularly acute lymphoblastic leukemia (ALL), can be cured with intensive chemotherapy, administered by fully trained interdisciplinary teams in specialized hospital units. Cooperation and collaboration at both national and international levels has helped to achieve this success [1], [2], [3] The costs of such intensive therapy has been calculated at between 100,000–200,000 USD in high income countries (HICs) where health services are free at the point of care, paid by the public sector and /or insurance schemes which cover most but not necessarily all of such costs [4]. Even in HICs there are still significant “out of pocket expenses” incurred by families in many countries, for example in Canada [5], [6]. In sharp contrast survival in low-middle income countries ranges between 10 and 30% [7], [8]. Delays in diagnosis due to public and professional lack of awareness of the meaning of signs and symptoms of disease and hence late referral, advanced stage of disease at presentation and high levels of treatment refusal/abandonment by families all contribute to this decreased survival [9], [10], [11]. Each of these factors and the reasons for them need to be understood and strategies developed to overcome them if the inequality of survival is to be reduced [9], [10], [11], [12].
The single most significant factor influencing survival is poverty (individual family, community and national) which limits availability of health education, resources, facilities,training and the ability to afford the cost of treatment [7], [8], [10], [11], [12]. In spite of the rising incidence of childhood cancer in developing countries as deaths from communicable diseases are gradually reduced [13], [14], relatively high treatment costs preclude a large number of children living in such low-middle income countries from obtaining appropriate and complete treatment for cancer. Although treatment of childhood ALL has improved with consistent therapy using specific protocols, after achievement of complete remission, patients do require phases of intensive therapy and then outpatient treatment for a further 2 years. Consequently non-compliance with treatment schedules, particularly due to “financial abandonment”, is a major problem [10], [11], [15].
Bangladesh has made huge progress in reducing maternal and under—5 mortality rates, in reducing family sizes and starting the demographic transition to middle income status. However in 2013 per capita income was 1044 USD compared to a world average of 8985 USD and there is no public sector healthcare provision, with the majority of medical bills being paid by patients and families [16]. In order to drive fiscal policy, particularly to relatively more expensive areas of healthcare,such as childhood cancers, it is essential to understand the macro-economic impact of these cancers.
There have been few actual previously published reports on the cost of ALL treatment worldwide and none from Bangladesh. This has made realistic counselling of parents and patients very difficult at the time of initial diagnosis if they have to carry the full financial burden. It also makes policy planning in the context of essential medicines, national fiscal policy towards childhood cancer and donor policy difficult without any reliable estimates of costs. In this paper we address this lacuna in the specific field of childhood cancers, in a low income setting, by analyzing the real world economic costs in Bangladesh of treating ALL.
Section snippets
Patients
50 unselected children with ALL were serially recruited to the economic study between 2010 and 2011 from the Department of Pediatric Hematology and Oncology at the BSMMU Hospital. Exclusions included those children who had central nervous system (CNS) and/or testicular involvement at diagnosis and those who do not achieve complete remission at the end of induction therapy. These complications inevitably decrease the chance of survival and increase costs considerably and if included would skew
Investigations costs
For the initial diagnostic investigations (full blood count/film; bone marrow morphology; chest X-ray, basic biochemistry and cerebro-spinal fluid analysis) the average cost was 33 USD (BDT 2315) with a range of 24–112 USD depending on whether immuno-phenotyping was performed (cost 85 USD = BDT 6000). All of these investigations were carried out “in house” at BSMMU. Patients sometimes came having had some investigations already performed elsewhere, which added to the family’s cost but it was not
Discussion
This study was set up initially to determine the financial impact on parents of children with acute lymphoblastic leukaemia (diagnosed at BSMMU Hospital) regarding treatment costs along with other “out of pocket” expenses, since no such information was previously available. Such information could not only be used to advise future parents but also inform both national and donor policymaking to ensure affordable care for children with ALL.
Using this modified ALL protocol, which forgoes some of
Conflict of interest
Professor Tim Eden has no conflicts of interest to declare and is not a paid employee of the hospital where this work was carried nor received any monies for the research or publishing of this article. He has been responsible as the corresponding author for writing the paper and its editing.
Professor Afiqul Islam is head of the unit at BSMMU where this research was carried out and supervised the research project. He received no financial gain for this work and has no conflict of interest to
Acknowledgements
We wish to thank all the parents of children with leukaemia at BSMMU who agreed to participate in this study and for all the members of the department who assisted to make it possible. We wish to thank World Child Cancer for developing the Twinning programme which has enabled the unit to make some progress and to all who support the department and Professor Richard Sullivan for his support of this study.
References (34)
- et al.
Children with cancer: driving the global agenda
Lancet Oncol.
(2013) - et al.
Baseline status of paediatric oncology care in ten low income and middle income countries receiving My Child Matters support: a descriptive study
Lancet Oncol.
(2008) - et al.
Abandonment of treatment for childhood cancer: a position statement of a SIOP PODC Working Group
Lancet Oncol.
(2011) - et al.
Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the children’s cancer group (CCG) 1952 study for standard-risk ALL
Blood
(2006) - et al.
Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomized controlled trial
Lancet Oncol.
(2013) - et al.
Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group
Blood
(2011) - et al.
Early post induction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group
Blood
(2008) - et al.
North-South twinning in pediatric hematology-oncology: the La Mascota programme: Nicaragua
Lancet
(1998) - et al.
Medicine prices, availability in 36 developing and middle-income countries: a secondary analysis
Lancet
(2009) - et al.
Pediatric cancer in the new millennium: dramatic progress, new challenges
Oncology
(2007)
Treatment of acute lymphoblastic leukemia
N. Engl. J. Med.
Cost analysis of the treatment of acute childhood lymphoblastic leukemia according to Nordic protocols
Acta Paediatr.
The monetary costs of childhood cancer to the families of patients
Int. J. Oncol.
The cost of childhood cancer from the family’s perspective: a critical review
Pediatr. Blood Cancer
Pediatric cancer in low-income and middle-income countries
Lancet Oncol.
International twinning partnerships: An effective method of improving diagnosis,treatment and care for children with cancer in low-middle income countries
J. Cancer Policy
Influence of socio-economic status on childhood acute lymphobastic leukemia treatment in Indonesia
Pediatrics
Cited by (21)
The UK's contribution to cancer control in low-income and middle-income countries
2021, The Lancet OncologyAre essential medicines available, reliable and affordable in low-middle income countries?
2019, Journal of Cancer PolicyCitation Excerpt :Apart from the two countries with state funding and Tanzania where all drug costs are funded by a charity (TLM) only in Bangladesh did the doctors know for sure the cost of drugs due to a recent study conducted there. Drug costs amounted to 48.6% of family out of pocket expenses in the hospital surveyed [18]. The doctors were asked (in Question15) for their perception of all the challenges to ensure that every patient could be treated with reliable and affordable medicines for curative, supportive and palliative care.
Development of paediatric oncology shared-care networks in low-middle income countries
2018, Journal of Cancer PolicyCitation Excerpt :Clearly the major challenges are to obtain hospital administration support and even more importantly, governmental support and financing for such developments. Without universal health coverage, the cost of treating a child with cancer falls on the families [12,13] but service delivery must be the duty of health providers and governments. Ribeiro et al. reported that 5-year survival for children in 10 low to middle-income countries was directly proportional to per capita annual total health expenditure, per capita gross domestic product, per capita gross national income, number of physicians and nurses per 1000 population and annual governmental health–care expenditure per capita [14].
Global efforts toward the cure of childhood acute lymphoblastic leukaemia
2018, The Lancet Child and Adolescent HealthCitation Excerpt :Two studies from the past 5 years,137,138 which used threshold analyses and global-costing procedures, suggest that treating childhood cancers in low-income and middle-income countries as per WHO criteria is very cost-effective. Few formal micro-costing studies have been done specifically analysing ALL, with published reports, each using different costing procedures, showing a wide variation in treatment costs, from US$3000 in Bangladesh,139 to $10 000–20 000 in Brazil,137 Mexico,140 and China,141,142 and $100 000 in North America and Europe.143 A substantial proportion of the costs (up to 50% in many cases) are associated with diagnostics, supportive care, and treatment in hospital.
Gender differences in leukemia outcomes based on health care expenditures using estimates from the GLOBOCAN 2020
2023, Archives of Public Health